Consolidated Portfolio Review Corp buys 227 shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Consolidated Portfolio Review Corp grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 63.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 587 shares of the medical research company’s stock after acquiring an additional 227 shares during the period. Consolidated Portfolio Review Corp’s holdings in Thermo Fisher Scientific were worth $325,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the company. Signature Resources Capital Management LLC boosted its stake in Thermo Fisher Scientific by 318.2% in the second quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 35 shares during the period. Northwest Financial Advisors bought a new position in Thermo Fisher Scientific in the 4th quarter valued at about $29,000. True Wealth Design LLC boosted its stake in Thermo Fisher Scientific by 1,275.0% in the fourth quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 51 shares during the last quarter. New Millennium Group LLC purchased a new stake in shares of Thermo Fisher Scientific in the second quarter valued at approximately $29,000. Finally, Stephens Consulting LLC boosted its holdings in Thermo Fisher Scientific by 116.0% in the second quarter. Stephens Consulting LLC now owns 54 shares of the medical research company’s stock worth $30,000 after purchasing an additional 29 shares in the last quarter. Institutional investors own 89.23% of the company’s shares.

Thermo Fisher Scientific stock rose 0.6%

TMO opened at $615.07 on Monday. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $622.30. The company has a 50-day moving average price of $578.71 and a 200-day moving average price of $576.22. The company has a quick ratio of 1.37, a current ratio of 1.72, and a debt-to-equity ratio of 0.64. The company has a market cap of $234.78 billion, a PE ratio of 39.45, a price-to-earnings-growth ratio of 2.86 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report ) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The firm had revenue of $10.54 billion for the quarter, compared to analyst estimates of $10.50 billion. In the same period last year, the company posted earnings of $5.15 per share. The company’s revenue fell 1.4% year-over-year. Sell-side analysts expect that Thermo Fisher Scientific Inc. to post 21.72 earnings per share for the current fiscal year.

Thermo Fisher Scientific announces dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be paid a dividend of $0.39 per share. The ex-dividend date is Friday, September 13. This represents a dividend of $1.56 on an annualized basis and a yield of 0.25%. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Analysts set new price targets

Several analysts recently commented on TMO shares. Evercore ISI decreased their price objective on Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Stifel Nicolaus lifted their price target on shares of Thermo Fisher Scientific from $600.00 to $615.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Robert W. Baird upped their price target on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Raymond James upped their price objective on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Finally, Royal Bank of Canada upped their target price on Thermo Fisher Scientific from $660.00 to $664.00 and gave the stock an “outperform” rating in a research note on Thursday, the 25th July. Four analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $630.41, according to MarketBeat.com.

Get the latest stock analysis on TMO

Insider buying and selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed via this hyperlink. In related news, VP Lisa P. Britt sold 3,624 shares of the stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $613.02, for a total value of $2,221,584.48. Following the completion of the transaction, the vice president now directly owns 13,699 shares in the company, valued at $8,397,760.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $76,420,473.36. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,084 shares of company stock worth $14,094,292. Insiders own 0.34% of the company’s shares.

About Thermo Fisher Scientific

(Free report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics and laboratory products and biopharmaceutical services in North America, Europe, Asia-Pacific and internationally. The company’s Life Sciences Solutions segment provides reagents, instruments and supplies for biological and medical research, drug and vaccine discovery and production, and infection and disease diagnosis; and solutions include biosciences, genetic sciences and biological manufacturing for the pharmaceutical, biotech, agricultural, clinical, healthcare, academic and government markets.

Recommended articles

Want to see what other hedge funds TMO owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).

Get news and reviews for Thermo Fisher Scientific Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Thermo Fisher Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.